H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Climb Bio (CLYM) with a Buy rating and $9 price target The firm views Climb Bio as a “disruptive innovator” in the field of B cell-mediated autoimmune diseases. Comparable valuations “hint at considerable upside potential” for the shares, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: